Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 01/18 05:39:49 pm
64.47 EUR   +0.26%
11:02a UCB : Transparency notification
11:02a UCB : Transparency Notification
11:02a UCB : Transparency notification
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
01/12/2017 01/13/2017 01/16/2017 01/17/2017 01/18/2017 Date
64.44(c) 65.4(c) 64.25(c) 64.3(c) 64.47(c) Last
343 525 249 688 259 708 295 725 213 456 Volume
-2.53% +1.49% -1.76% +0.08% +0.26% Change
More quotes
Financials (€)
Sales 2016 4 059 M
EBIT 2016 750 M
Net income 2016 473 M
Debt 2016 910 M
Yield 2016 1,89%
Sales 2017 4 323 M
EBIT 2017 904 M
Net income 2017 582 M
Debt 2017 563 M
Yield 2017 2,08%
P/E ratio 2016 24,56
P/E ratio 2017 19,92
EV / Sales2016 3,31x
EV / Sales2017 3,02x
Capitalization 12 507 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
11:02a UCB : Transparency notification
11:02a UCB : Transparency notification
11:02a UCB : Transparency Notification
11:02a UCB : Transparency notification
11:02a UCB : Transparency notification
11:02a UCB : Transparency notification
01/06 Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
01/05 DERMIRA : Elects Emmanuel Caeymaex to Board of Directors
2016 DERMIRA,INC. (NASDAQ : DERM) Files An 8-K Departure of Directors or Certain Offi..
2016 UCB : Second CIMZIA (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- Update
More sector news : Pharmaceuticals - NEC
Latest Tweets
11:02aUCB : Transparency notification  
11:02aUCB : Transparency notification  
11:02aUCB : Transparency notification  
11:02aUCB : Transparency Notification  
01/17Briefing actions (17/1) - AB InBev, KBC, UCB, Galapagos, Solvay, Ahold, Ablyn..
1
More tweets
Qtime:30
News from SeekingAlpha
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Marketing application filed in Japan for osteoporosis candidate romosozumab
2016 Late-stage study shows Amgen and UCB's romosozumab significantly increases bo..
2016 AMGEN GETS BUSY; MANY NEWS ITEMS : Anything Good Yet?
2016 UCB S.A. 2016 Q1 - Results - Earnings Call Slides
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 76,7 €
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB5.57%13 358
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results